Health & Pharma
Modeling & Simulation Gains Traction for Complex Drug Dosing
The U.S. Food and Drug Administration (FDA), in collaboration with the International Society of Pharmacometrics (ISoP), held a public workshop to discuss the application of modeling and simulation (M&S) for selecting dosages. The focus was on two complex areas: combination therapies (using multiple drugs together) and label expansion (approving an existing drug for a new disease or population). This event indicates a growing regulatory acceptance of computational methods to supplement traditional clinical trials, aiming to improve the efficiency and precision of drug development by getting dose selection right earlier in the process.
Published
Updated
Access
Evidence strength
Time horizon
Impact
Evidence
§What changed
The FDA's co-hosting of a public workshop on November 9, 2023, specifically dedicated to using modeling and simulation for dose selection in complex therapeutic scenarios, represents a formal and public engagement on the topic. It moves the conversation about computational pharmacology from a niche academic discussion to a subject of direct regulatory interest, suggesting an increasing openness to these methods within the drug approval framework.
§Why it matters
Relying more on modeling and simulation could accelerate drug development timelines, reduce costs associated with extensive clinical trials, and lead to more optimized and safer dosing regimens. For pharmaceutical companies, this could mean a faster path to market for complex treatments. For patients, it could mean quicker access to more effective and personalized therapies, especially in areas like oncology where combination treatments are common.
§What most people may be missing
This discussion is not about entirely replacing clinical trials with computers. It is about integrating sophisticated modeling into the development process to make trials smarter and more efficient, particularly for the critical step of dose selection. Getting the dose right early via better modeling can prevent late-stage trial failures and improve a drug's overall safety and efficacy profile. The goal is to augment human expertise and clinical data, not replace them.
§What to watch next
- Issuance of new FDA draft or final guidance documents on the use of M&S for dose selection in drug development.
- Increased inclusion of M&S data in New Drug Applications (NDAs) and Biologics License Applications (BLAs), particularly for combination therapies.
- Public statements or case studies from pharmaceutical companies highlighting the successful use of M&S to guide dose-finding studies.
- Further workshops or collaborations between the FDA and pharmacometrics organizations, indicating sustained momentum.
§Skeptical view
A skeptical view holds that while modeling and simulation are useful tools, they are only as good as the data and assumptions they are built upon. Over-reliance on computational models without sufficient real-world clinical data could lead to unforeseen safety issues or suboptimal efficacy in diverse patient populations. Critics argue that biological systems are too complex to be perfectly simulated and that these methods must remain strictly supplementary to, and not a replacement for, rigorous, large-scale clinical trials.
§Key facts
- The FDA and the International Society of Pharmacometrics (ISoP) co-hosted a public workshop on November 9, 2023.
- The workshop's focus was on 'Using Modeling and Simulation to Select Dosages for Combination Therapies and New Indications'.
- The event brought together stakeholders to discuss dose selection strategies, regulatory perspectives, and case studies involving M&S.
- The FDA's Office of Clinical Pharmacology, a key department in drug evaluation, was a primary organizer of the event.
§Evidence and sources
Citations link to the primary sources used to compile this signal.